| ANWPX | NFACX | ANWPX / NFACX | |
| Total Expense Ratio | 0.71 | 1.87 | 38% |
| Annual Report Gross Expense Ratio | 0.71 | 1.96 | 36% |
| Fund Existence | 53 years | 16 years | - |
| Gain YTD | 6.090 | 6.923 | 88% |
| Front Load | 6% | N/A | - |
| Min. Initial Investment | 250 | 1000 | 25% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 172B | 830M | 20,723% |
| Annual Yield % from dividends | 0.96 | 0.00 | - |
| Returns for 1 year | 8.49 | 4.11 | 207% |
| Returns for 3 years | 38.66 | 49.08 | 79% |
| Returns for 5 years | 14.40 | 0.38 | 3,793% |
| Returns for 10 years | 116.90 | -27.46 | -426% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| FBTIX | 50.96 | 1.28 | +2.58% |
| Fidelity Advisor Biotechnology I | |||
| IVFCX | 4.81 | 0.09 | +1.91% |
| Federated Hermes Intl Strat Val Div C | |||
| ECASX | 24.40 | 0.35 | +1.46% |
| Eaton Vance Atlanta Capital SMID-Cap C | |||
| JHACX | 10.22 | 0.01 | +0.10% |
| JHancock Multi-Asset Absolute Return C | |||
| EVCGX | 15.90 | -0.26 | -1.61% |
| Eaton Vance China Equity A | |||